You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
OncoCyte will cease further development of a liquid biopsy test that used an immune system interrogation approach to clarify whether patients’ lung nodules are benign.
The tests were developed by Psomagen, Acupath Laboratories, and BioTNS, and the nasal swab self-collection kit is offered by Kroger Health.
The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.
In a separate study, researchers studying the use of Oncotype DX in African-American men found it to be predictive of disease outcomes regardless of race.
Through its Access to COVID-19 Tools-Accelerator program, or ACT-A, WHO hopes to quickly identify and scale up high performing rapid antigen-based diagnostics.
Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.
RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.
Cowen said that Hologic is on track to more than double its Panther system placements to about 500 this year, driven by SARS-CoV-2 test demand.
Proscia'a digital pathology platform allows pathologists to view, manage, and analyze whole-slide images and is interoperable with laboratory information systems.
The firm said in an SEC document that it received an FDA warning letter in connection with the agency's requirements for its Verigene SP instrument.
Lexent's technology integrates low-pass whole-genome sequencing, fragmentomics, and DNA methylation to detect early stage disease.
The PCR-based test is based on the US Centers for Disease Control and Prevention's CDC 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel.
The test is based on the US Centers for Disease Control and Prevention's SARS-CoV-2 panel and detects two regions of the virus' nucleocapsid gene.
FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.
Both tests are authorized for use by any laboratory CLIA certified to perform high-complexity tests, according to the FDA.
The Energy and Commerce Committee chairman asked the agency to show Congress all of the state and local plans for COVID-19 testing by July 6.
The investment bank said CareDx's products are gaining traction and that the stock is positioned for 20 percent to 30 percent growth over the next few years.
The firm used the new loan to pay off an older $7.0 million loan and a $3.0 million promissory note held by Qiagen North American Holdings.
For the three months ended March 31, the firm reported revenues of $9.2 million, up from $6.0 million in the year-ago quarter and beating the consensus Wall Street estimate of $8.9 million.
The firm said that its RAQ SARS-CoV-2 PCR Kit allows the replacement of full nucleic acid extraction with a simple heat treatment, decreasing sample processing time.